Diabetes Education News

Use of a DPP-IV inhibitor, SGLT2 inhibitor or GLP-1 receptor agonist does not increase risk for diabetic macular edema among adults with type 2 diabetes and diabetic retinopathy, according to study data.

The FDA is warning providers and patients that dosing errors with compounded injectable semaglutide may be leading to adverse events, according to a press release.

There are many important factors primary care providers must consider when prescribing popular anti-obesity medications, according to experts.

A voluntary medical device correction has been issued for a small number of continuous glucose monitoring sensors distributed in the first half of May, according to an industry press release.

Changing in-hospital nutritional insulin administration from before meals to after meals lowered hypoglycemia rates at a community hospital, according to study findings published in Diabetes Research and Clinical Practice.

An immunotherapy to treat type 1 diabetes for people with the human leukocyte antigen DR3-DQ2 genotype received its second fast-track designation from the FDA, according to a company press release.

Women with polycystic ovary syndrome and high androgen levels may have a higher risk for liver disease than those with PCOS and normal androgen levels, according to an analysis of UK Biobank data.

Individuals who develop type 1 diabetes during childhood experienced greater risk for several mental health conditions later in life, including anxiety disorders and substance use disorders, study results showed.

New prescriptions of GLP-1 receptor agonists for the treatment of obesity have increased significantly among individuals without type 2 diabetes in the last decade, according to a study in Annals of Internal Medicine.

Semaglutide was not associated with increased risks for adverse neurologic or psychological disorders at 1 year compared with other diabetes drugs, according to data published in eClinicalMedicine.